Attached files
file | filename |
---|---|
EX-99.2 - CORPORATE PRESENTATION - INNOVUS PHARMACEUTICALS, INC. | ex99-2.htm |
EX-10.1 - BERHOLTZ EMPLOYMENT AGREEMENT - INNOVUS PHARMACEUTICALS, INC. | ex10-1.htm |
8-K - FORM 8-K - INNOVUS PHARMACEUTICALS, INC. | innv8k_jan42017.htm |
Exhibit 99.1
Innovus Pharma Expands its Executive Management Team with the
Addition of
Randy Berholtz as its Executive Vice President, Corporate
Development and
General Counsel
Pharma Corporate and Legal veteran Berholtz comes on board as
Innovus expands its
corporate development and commercialization efforts
San
Diego, Calif., January 6, 2017 – Innovus Pharmaceuticals, Inc.
("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging
commercial stage pharmaceutical company that delivers safe,
innovative and effective over-the-counter medicine and consumer
care products to improve men’s and women’s health and
respiratory diseases, today announced that Randy Berholtz will join
the management team as Executive Vice President, Corporate
Development and General Counsel effective January 9, 2017. A life
sciences business and legal veteran with decades of experience,
Berholtz joins Innovus Pharma to expand its corporate development
efforts to find and enter into additional collaborations to expand
the breadth and depth of product offerings on a worldwide
basis.
“I
am very excited to bring on Randy at this important period of
commercial growth for Innovus Pharma,” said Dr. Bassam Damaj,
Innovus’ Chief Executive Officer. “His business, legal
and deal-making expertise and experience will help us to increased
our capacity to find, negotiate with and enter into additional
acquisitions and partnerships that will help us increase our
product offerings and expand our international commercialization
efforts to take our company to the next stage.”
"I am
very excited to be joining the Innvous Pharma exexcutive team at
this important point in the Company’s growth,” said
Berholtz. “I look forward to working with Bassam, Robert
Hoffman and the entire Innovus Pharma team on growing the
Company’s product portfolio, expanding its corporate
partnerships and increasing its revenues.”
Berholtz
will oversee Innovus Pharma’s corporate development, business
development and legal areas.
Mr.
Berholtz was recently the founding partner of the Sorrento Valley
Law Group, a healthcare and life sciences law firm and had
previously been a part-time consultant for the Company from July
2013 to mid-May 2016. Previously, from 2011 to 2013, he was the
Executive Vice President, General Counsel and Secretary of Apricus
Biosciences, Inc., a biotechnology company (Nasdaq:APRI); from 2004
to 2010, he was the Vice President, General Counsel and Secretary
of the ACON Group of private U.S. and Chinese life science
companies; from 2003 to 2004, he was the Chief Operating Officer
and General Counsel to Inglewood Ventures, a life sciences venture
capital firm; and from 2000 to 2003, he held multiple titles and
rose to become the Acting General Counsel and Secretary of Nanogen,
Inc., a genomics tools company (Nasdaq:NGEN). From 1992 to 2000,
Mr. Berholtz was in private practice with law firms in New York and
San Diego and from 1990 to 1991, he was a law clerk to Judge Jerry
E. Smith on the U.S. Court of Appeals for the Fifth
Circuit.
Mr.
Berholtz is a member of the board of directors of Hispanica
International Delights of America, Inc., an ethnic food company
(OTC:HISP) and Larada Health, Inc., a private company in the
medical supply business and is a Senior Advisor to Mesa Verde
Ventures, a life sciences venture capital firm. Mr. Berholtz
received his B.A. from Cornell University, his M.Litt. from Oxford
University where he was a Rhodes Scholar, his J.D. from Yale
University and his M.B.A. from the University of San
Diego.
About Innovus Pharmaceuticals, Inc.
Headquartered
in San Diego, Innovus Pharma is an emerging commercial stage
pharmaceutical company delivering over-the-counter medicines and
consumer care products for men's and women's health and respiratory
diseases. The Company generates revenues from its lead products (a)
BTH® Testosterone Booster, (b) BTH® Human Growth Agent,
(c) Zestra® for female arousal and (d) EjectDelay® for
premature ejaculation and has an additional five marketed products
in this space, including (e) Sensum+® to help with reduced
penile sensitivity, (f) Zestra Glide®, (g)Vesele® for
promoting sexual health, (h) RecalMax™ for promoting brain
and cognitive health, (i) Androferti® (in the US and Canada)
to support overall male reproductive health and sperm quality, (j)
BTH Vision Formula, (k) BTH Blood Sugar, among others and
eventually FlutiCare™ OTC for allergic rhinitis, if its ANDA
is approved by the U.S. FDA.
For
more information, go to www.innovuspharma.com,
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com; www.urivarx.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements
under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company,
including, but not limited to, additional acquisitions, commercial
partnerships, and to achieve its other development,
growth, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on
these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company's most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with
the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
# #
#
Contact:
Kevin
Holmes
Chesapeake
Group
410-825-3930
info@chesapeakegp.com
###